Say what? Allergan just agreed to pay a 6X cash premium for Tobira and its troubled PhIII NASH drug
A couple of months after a trial setback crushed Tobira’s share price, Allergan $AGN has swooped in to buy the company for $29.35 a share …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
